Nathanial Ross Liddy

Title: Nathanial Ross Liddy: Innovator in T Cell Receptor Technology

Introduction

Nathanial Ross Liddy is a prominent inventor based in Abingdon, GB. He is known for his significant contributions to the field of immunology, particularly in the development of T cell receptor (TCR) technology. His innovative work has the potential to advance therapeutic strategies in cancer treatment.

Latest Patents

Liddy holds a patent for a non-naturally occurring T cell receptor. This TCR has the unique property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex. The invention is characterized by TCR alpha and/or beta variable domains that are mutated relative to a reference TCR. Notably, this TCR exhibits a binding affinity and/or binding half-life for the YLEPGPVTA-HLA-A2 complex that is at least double that of a reference TCR. The patent also describes embodiments of the invention, including the use of such TCRs in adoptive therapy and their fusion with therapeutic agents.

Career Highlights

Nathanial Liddy is associated with Immunocore Limited, a company that focuses on developing innovative TCR-based therapies. His work at Immunocore has positioned him as a key player in the advancement of immunotherapy.

Collaborations

Liddy has collaborated with notable colleagues, including Bent Karsten Jakobsen and Naomi Harwood. Their combined expertise contributes to the innovative research and development efforts at Immunocore.

Conclusion

Nathanial Ross Liddy is a distinguished inventor whose work in T cell receptor technology is paving the way for new therapeutic approaches in cancer treatment. His contributions are significant in the field of immunology and hold promise for future advancements.